In our recent publication in Scientometrics, Maureen McKelvey (University of Gothenburg) and myself explore whether the reputation and the impact of scientific publications originating in firms benefit from R&D alliances with different types of partners. Our results suggest that biotechnology and pharmaceutical firms should focus on establishing R&D alliances with pharmaceutical firms in order to increase the probability of publishing in journals with a high reputation. However, in terms of scientific impact, i.e., forward citations, publications originating in firms do not benefit from having access to different types of alliance partners. Our study can be found here.